HLA and drug-induced toxicity

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 3, 2009, Pages 231-242

  Phillips, Elizabeth J ^a,b,c   Mallal, Simon A ^a,c  

^a ROYAL PERTH HOSPITAL   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

Author keywords

Abacavir; Allopurinol; Carbamazepine; Drug hypersensitivity; HLA; Nevirapine; Pharmacogenetics

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ALLOPURINOL; AMINOPENICILLIN; ANTICONVULSIVE AGENT; AUROTHIOMALATE; CARBAMAZEPINE; CLOZAPINE; EFAVIRENZ; FLUCLOXACILLIN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HYDRALAZINE; LEVAMISOLE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PENICILLAMINE; PHENOBARBITAL; PHENYTOIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFAMETHOXAZOLE; SULFONAMIDE; XIMELAGATRAN;

AGRANULOCYTOSIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIGEN PRESENTING CELL; ASTHMA; CD8+ T LYMPHOCYTE; COST EFFECTIVENESS ANALYSIS; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG METABOLISM; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GOUT; HEPATITIS; HLA SYSTEM; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; LABORATORY TEST; MYASTHENIA GRAVIS; NONHUMAN; PROTEINURIA; QUALITY CONTROL; REVIEW; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; GENETIC SCREENING; HISTOCOMPATIBILITY ANTIGENS; HIV INFECTIONS; HUMANS; PHARMACOGENETICS;

EID: 67650239766     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ, Povey S, Talbor CC Jr, Wright MW, Wain HM et al: Gene map of the extended MHC. Nat Rev Genet (2004) 5(12):889-899.
2. Rudoph MG, Stanfeld RL, Wilson IA: How TCRs bind MHCs, peptides and coreceptors. Ann Review Immunol (2006) 24:419-466.
3. Meyer D, Single RM, Mack SJ, Erlich HA, Thomson G: Signatures of demographic history and natural selection in the human major histocompatibility complex loci. Genetics (2006) 173(4):2121-2142.
4. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM et al: A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet (1996) 13(4):399-408.
5. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Marmotte C, Maxell D, James I et al: Association between presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet (2002) 359(9308):727-732.
6. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME et al: Genetic variation in HLA-B region and hypersensitivity reactions to abacavir. Lancet (2002) 359(9312):1121-1122.
7. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ et al: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA (2005) 102(11):4134-4139.
8. Romano A, De Santis A, Romito A, Di Fonso M, Venuti A, Gasbarrini GB, Manna R: Delayed hypersensitivity to aminopenicillins is related to major histocompatibilty complex genes. Ann Allergy Asthma Immunol (1998) 80(5):433-437.
9. Donaldson PT, Bhatnagar P, Graham J, Henderson J, Leathart JB, Pirmohamed M, Bernal W, Aithal GP, Day CP, Daly AK: Flucloxacillin-induced liver injury: The extended MHC 57.1 haplotype as a major risk factor. Abstr AASLD (2008) 59:Abs 196.
10. Roujeau JC, Huyn TN, Bracq C, Guillaume JC, Revuz J, Touraine R: Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol (1987) 123(9):1171-1173.
11. Ozkaya-Bayazit E, Akar U: Fixed drug eruption induced by trimethoprim-sulfamethoxazole: Evidence for a link to HLA-A30 B13 Cw6 haplotype. J Am Acad Dermatol (2001) 45(5):712- 717.
12. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT: Medical genetics: A marker for Stevens-Johnson syndrome. Nature (2004) 428(6982):486.
13. Pirmohamed M, Lin K, Chadwick D, Park BK: TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology (2001) 56(7):890-896.
14. Alfrevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M: HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics (2006) 7(6):813-818.
15. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF et al: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics (2006) 16(4):297-306.
16. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E, Shumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC, RegiSCAR Group: A marker for Stevens-Johnsons syndrome: Ethnicity matters. Pharmacogenomics J (2006) 6(4):265-268.
17. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MH: Association between HLA-B*1502 and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia (2007) 48(5):1015-1018.
18. Locharenkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, Kangwanshiratada O, Hirankarn N, Suphapeetiporn K, Shotelersuk V: Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia (2008) 49(12):2087-2091.
19. Kim SH, Choi JH, Lee KW, Kim SH, Shin ES, Oh HB, Suh CH, Nahm DH, Park HS: The human leucocyte antigen DRB1*1302-DQB1*0609- DPB1*0201 haplotype may be a strong genetic marker for aspirin induced urticaria. Clin Exp Allergy (2005) 35(3):339-344.
20. Kim SH, Ye M, Lee SK, Park HS: Genetic mechanisms of aspirininduced urticaria/angioedema. Curr Opin Allergy Clin Immunol (2006) 6(4):266-270.
21. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ: HLA-B38, DR4, DQw3 and clozapine induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry (1990) 47(10):945-948.
22. Rodriguez-Pérez M, González-Dominguez J, Matarán L, Garcia-Pérez S, Salvatierra D: Association of HLA-DR5 with mucocutaneous lesions in patients with rheumatoid arthritis receiving gold sodium thiomalate. J Rheumatol (1994) 21(1):41-43.
23. Speerstra F, Reekers P, Van de Putte LB, Vandenbroucke JP: HLA associations in aurothioglucose- and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis. Tissue Antigens (1985) 26(1):35-40.
24. Batchelor JR, Welsh KI, Tinoco RM, Dollery CT, Hughes GR, Bernstein R, Ryan P, Naish PF, Aber GM, Bing RF, Russell GI: Hydralazine-induced systemic lupus erythematosis: Infuence of HLA-DR and sex on susceptibility. Lancet (1980) 1(8178):1107-1109.
25. Diez RA: HLA-B27 and agranulocytosis by levamisole. Immunol Today (1990) 11(8):270.
26. Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, Phillips E, Christiansen FT, Mallal S: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T cell count. AIDS (2005) 19(1):97-99.
27. Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, Corso N, Casula B, La Nasa G, Contu L, Manconi PE: HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS (2006) 20(12):1621-1626.
28. Gatanaga H, Yazaki H, Tanuma J, Honda M, Genka I, Teruya K, Tachyikawa N, Kikuchi Y, Oka S: HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS (2007) 21(2):264-265.
29. Vitezica ZG, Milpied B, Lonjou C, Borot N, Ledger TN, Lefebrve A, Hovnanian A: HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS (2008) 22(4):540-541.
30. Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, Tantisiriwat W, Charoenyingwattana A, Sura T, Chantratita W, Nakamura Y: HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics (2009) 9(2):139-146.
31. Quiralte J, Sánchez-Garcia F, Torres MJ, Blanco C, Castillo R, Ortega N, de Castro FR, Pérez-Aciego P, Carillo T: Association of HLA-DR11 with the anaphylactoid reaction caused by nonsteroidal anti-infammatory drugs. J Allergy Clin Immunol (1999) 103(4):685-689.
32. Pachoula-Papasteriades C, Boki K, Varla-Leftherioti M, Kappos-Rigatou I, Fostiropoulos G, Economidou J: HLA-A-B, and -DR antigens in relation to gold and D-penicillamine toxicity in Greek patients with RA. Dis Markers (1986) 4(1-2):35-41.
33. Garlepp MJ, Dawkins RL, Christiansen FT: HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis. Br Med J (Clin Res Ed) (1983) 286(6362):338-340.
34. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bnegtsson OF, Andersson TB, Carlsson S, Ceederbrant KE, Gibson NJ, Armstrong M, Lagerström-Fermier ME et al: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmaocgenomics J (2008) 8(3):186-195.
35. Mytilineos J, Scherer S, Dunckley H, Trejaut J, Chapman J, Fischer G, Fae I, Middleton D, Savage D, Bignon JD, Bensa JC et al: DNA HLA-DR typing results of 4000 kidney transplants. Transplantation (1993) 55(4):778-781.
36. Gomes ER, Demoly P: Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol (2005) 5(4):309-316.
37. Edwards JR, Aronson JK: Adverse drug reactions: Defnitions, diagnosis and management. Lancet (2000) 356(9237): 1255-1259.
38. Nakamura Y: Pharmacogenomics and drug toxicity. N Engl J Med (2008) 359(8):856-858.
39. Lavergne SN, Park BK, Naisbitt DJ: The roles of drug metabolism in the pathogenesis of T-cell mediated drug hypersensitivity. Curr Opin Allergy Clin Immunol (2008) 8(4):299-307.
40. Park BK, Naisbitt DJ, Gordon SF, Kitteringham NR, Primohamed M: Metabolic activation in drug allergies. Toxicology (2001) 158(1-2):11-23.
41. Bachot N, Roujeau JC: Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol (2003) 4(8): 561-572.
42. Chia FL, Leon KP: Severe cutaneous adverse reactions to drugs. Curr Opin Allergy Clin Immunol (2007) 7(4):304-309.
43. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK: The danger hypothesis - Potential role in idiosyncratic drug reactions. Toxicology (2002) 181-182:55-63.
44. Séguin B, Uetrecht J: The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol (2003) 3(4):235-242.
45. Pichler WJ: Modes of presentation of chemical neoantigens to the immune system. Toxicology (2002) 181-182:49-54.
46. Pichler WJ, Beeler A, Keller M, Lerch M, Posadas S, Schmid D, Spanou Z, Zawodniak A, Gerber B: Pharmacological interaction of drugs with immune receptors: The p-i concept. Allergol Int (2006) 55(1):17-25.
47. Edwards SG, Hubbard V, Aylett S, Wren D: Concordance of primary generalized epilepsy and carbamazepine hypersensitivity in monozygotic twins. Postgrad Med J (1999) 75(889):680-681.
48. Liechty CA, Solberg P, Mwima G, Were W, Weidle PJ, Mermin J: Nevirapine-induced Stevens-Johnson syndrome in a mother and son. AIDS (2005) 19(9):993-994.
49. Peyrieere H, Nicolas J, Siffert M, Demoly P, Hillaire-Buys D, Reynes J: Hypersensitivity related to abacavir in two members of a family. Ann Pharmacother (2001) 35(10):1291-1292.
50. Knowles SR, Shapiro LE, Shear NH: Anticonvulsant hypersensitivity syndrome: Incidence, prevention and management. Drug Saf (1999) 21(6):489-501.
51. Sierra NM, García B, Marco J, Plaza S, Hidalgo F, Bermejo T: Cross hypersensitivity syndrome between phenytoin and carbamazepine. Pharm World Sci (2005) 27(3):170-174.
52. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, Mockenhaupt M et al: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med (1995) 333(24):1600-1607.
53. Phillips E, Mallal S: Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol (2007) 7(4):324-330.
54. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G, Steel H: Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther (2001) 23(10):1603-1614.
55. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen F T, Purcell AW, McCluskey J et al: Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA (2004) 101(12):4180-4185.
56. Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z, Kjer-Nielsen L, Mifsud NA, Tait BD, Holdsworth R, Almeida CA et al: Human leucocyte antigen class I restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity (2008) 28(6):822-832.
57. Almeida CA, Martin AM, Nolan D, Lucas A, Cameron PU, James I, Phillips E, Mallal S: Cytokine profling in abacavir hypersensitivity patients. Antivir Ther (2008) 13(2):281-288.
58. Martin AM, Almeida CA, Cameron P, Purcell AW, Nolan D, James I, McCluskey J, Phillips E, Landay A, Mallal S: Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS (2007) 21(10):1233-1244.
59. Phillips EJ: Genetic screening to prevent abacavir hypersensitivity reaction: Are we there yet? Clin Infect Dis (2006) 43(1):103-105.
60. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A et al: A whole-genome association study of major determinants of host control of HIV-1. Science (2007) 317(5840):944-947.
61. Levy J: HIV pathogenesis: 25 Years of progress and persistent challenges. AIDS (2009) 23(2):147-160.
62. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, Nangle K, Scott T, Spreen WR, Warren LL, Roses AD: Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics (2004) 5(2):203-211.
63. DeJesus E, Herreera G, Teoflo E, Gerstoft J, Buendia CB, Brand JD, Brothers CH, Hernandez J, Castillo SA, Bonny T, Lanier ER et al: Abacavir versus zidovudine combined with lamivudine and efavirenz for the treatment of antiretroviralnaïve HIV-infected adults. Clin Infect Dis (2004) 39(7):1038-1046.
64. Guilick RM, Ribaudo H, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL et al: Three- versus four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial. J Am Med Assoc (2006) 296(7):769-781.
65. Hernendez J, Cutrell A, Bonny T, Castillo S, Brothers C, Hee J, Powell W, Scott T: Diagnosis of abacavir hypersensitivity reactions among patients not receiving abacavir in two blinded studies. Antivir Ther (2003) 8:Abs 134, L88.
66. Dart Trial Team: Twenty-four week safety and tolerability of nevirapine vs abacavir in combination with zidovudine/ lamivudine as frst-line antiretroviral therapy: A randomized double-blind trial (NORA). Trop Med Int Health (2008) 13(1):6-16.
67. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis (2006) 43(1):99-102.
68. Zucman D, Truchis P, Majerhole C, Stegman S, Caillat-Zucman S: Prospective screening for human leucocyte antigen B*5701 avoids abacavir hypersensitivity in the ethnically mixed French HIV population. J Acquir Immune Defc Syndr (2007) 45(1):1-3.
69. Reeves I, Churchill D, Fisher M: Screening for HLA-B*5701 reduces the frequencies of abacavir hypersensitivity reactions. Antiviral Ther (2006) 11(Suppl 3):14.
70. Trottier B, Thomas R, Nguyen VK, Machouf N: How effectively HLA screening can reduce the early discontinuation of abacavir in real life. Abstr IAS (2007) 4:Abs MOPEB002.
71. Waters LJ, Mandalia S, Gazzard B, Nelson M: Prospective HLA-B*5701 screening and abacavir hypersensitivity: A single centre experience. AIDS (2007) 21(18):2533-2534.
72. Young B, Squires K, Patel P, Dejesus E, Bellos N, Berger D, Sutherland-Phillips DH, Liao Q, Shaefer M, Wannamaker P: First large multicenter open-label study utilizing HLA-B*5701w screening for abacavir hypersensitivity in North America. AIDS (2008) 22(13):1673-1675.
73. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P et al: HLA-B*5701 screening for hypersensitivity to abacavir. N Eng J Med (2008) 358(6):568-579.
74. Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A et al: High sensitivity of human leucocyte antigen-B*5701 as a marker for immunologically confrmed abacavir hypersensitivity in white and black patients. Clin Infect Dis (2008) 46(7):1111-1118.
75. Phillips EJ, Sullivan JR, Knowles SR, Shear NH: Utility of patch testing in patients with hypersensitivity reactions associated with abacavir. AIDS (2002) 16(16):2223-2225.
76. Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, Martin AM, Mallal SA, Shear NH: Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS (2005) 19(9):979-981.
77. Phillips E, Nolan D, Thorborn D, Shaefer M, Laird R, Rauch A, Rachlis A, Shear N, Knowles S, Hughes A, Montaner J et al: Genetic factors predicting abacavir hypersensitivity and tolerance in HLA- B*5701 positive individuals. Eur J Dermatol (2008) 18:Abs 247.
78. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM et al: Antiretroviral treatment of adult HIV infection: 2008 Recommendations of the International AIDS Society-USA panel. J Am Med Assoc (2008) 300(5):555-570.
79. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents: Department of Health and Human Services, Washington DC, USA (2008). aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
80. Park WB, Choe PG, Song KH, Lee S, Jang HC, Jeon JH, Park SW, Park MH, Oh MD, Choe KW: Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir. Clin Infect Dis (2009) 48(3):365-367.
81. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE: The cost-effectiveness of HLA-B*5701 genotyping to guide initial antiretroviral therapy for HIV. AIDS (2008) 22(15):2025-2033.
82. Bamshad MJ, Olson SE: Does race exist? Sci Am (2003) 289(6): 78-85.
83. Altermann WW, Grondkowski V, Reichert S, Seliger B, Schlaf G: A novel HLA-B*57 (B*5714) allele in a healthy male Caucasian individual. Tissue Antigens (2008) 71(3):253-254.
84. Martin AM, Nolan D, Mallal S: HLA-B*5701 typing by sequence-specifc amplifcation: Validation and comparison with sequence-based typing. Tissue Antigens (2005) 65(6):571-574.
85. Shenton JM, Popovic M, Uetrecht JP: Nevirapine hypersensitivity. In: Drug Hypersensitivity. Pichler WJ (Ed), Karger AG, Basel, Switzerland (2007):115-128.
86. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ: Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos (1999) 27(12):1488-1495.
87. FDA public health advisory for nevirapine (Viramune): FDA, Silver Spring, MD, USA (2005). www.fda.gov/CDER/drug/advisory/nevirapine.htm
88. Shear NH, Milipied B, Bruynzeel DP, Phillips EJ: A review of drug patch testing and implications for HIV clinicians. AIDS (2008) 22(9):999-1007.
89. Kamaliah MD, Zainal D, Mokhtar N, Nazmi H: Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia. Int J Dermatol (1998) 37(7):520-523.
90. Hung SI, Chung WH, Chen YT: Genetics of severe drug hypersensitivity reactions in Han Chinese. In: Drug Hypersensitivity. Pichler WJ (Ed), Karger AG, Basel, Switzerland (2007):55-64.
91. Ueta M, Sotozono C, Tokunaga K, Yabe T, Kinoshita S: Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthamol (2007) 143(2):367-368.
92. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M et al: A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to fve high-risk drugs. Pharmacogenet Genomics (2008) 18(2):99-107.
93. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S et al: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics (2008) 9(11): 1617-1622.
94. Phillips E, Mallal S: Successful translation of pharmacogenetics into the clinic: The abacavir example. Mol Diagn Ther (2009) 13(1):1-9.
95. Hammond E, Mamotte C, Nolan D, Mallal S: HLA-B*5701 typing: Evaluation of an allele-specifc polymerase chain reaction melting assay. Tissue Antigens (2007) 70(1):58-61.
96. Martin AM, Krueger R, Almeida CA, Nolan F, Phillips E, Mallal S: A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet Genomics (2006) 16(5):353-357.
97. Kostenko L, Lucas A, Kjer-Neilsen L, Foley B, Nicholson I, Tait B, Holdsworth R, Rossjohn J, Mallal S, McCluskey J: A rapid and sensitive fow-based screening test for detection of HLA-B57 to avoid abacavir hypersensitivity. Abstr IAS (2007) 4:Abs WEPEB113LB.
98. Hammond E, Almeida CA, Mamotte C, Nolan D, Phillips E, Schollaardt TA, Gill MJ, Angel JB, Neurath D, Li J, Giulivi T et al: External quality assessment of HLA-B*5701 reporting: An international multicentre survey. Antivir Ther (2007) 12(7):1027-1032.